Olfax Medical
Olfax Medical is a start-up company based in Asheville, NC, specializing in developing and commercializing nasally administered therapeutics. Their mission is to revolutionize nasal drug delivery to help patients avoid the harmful and addictive side effects of systemic pharmaceuticals. They focus on creating self-administered treatments that utilize nerve networks in the nose to deliver neurologically active medications directly to the brain, bypassing the blood-brain barrier. Their innovative nasal AutomizerTM platform enables accurate, controlled delivery of medication to the upper-posterior nasal cavity, improving efficacy, speed, and comfort of treatment, especially for neurological conditions like migraine and headache disorders.
Industries
Nr. of Employees
small (1-50)
Products
Handheld propellant-free nasal delivery device for targeted posterior nasal dosing
A handheld device platform engineered to deliver consistent, controlled aerosolized medication to the upper-posterior nasal cavity using anatomical nozzle routing and a silicone-plate atomizing tip; designed for dual nostril dosing without propellants.
Self-administered single-use intranasal combination therapy for acute headache
A single-use, prescription combination product intended to translate clinic-based sphenopalatine ganglion (SPG) blockade into a patient self-administered intranasal therapy for rapid relief of acute migraine and cluster headache.
OFX-001
A self-administered, intranasal treatment designed to interrupt an acute pain attack in as little as 15 minutes by delivering medication to the upper-posterior nasal cavity.
Handheld propellant-free nasal delivery device for targeted posterior nasal dosing
A handheld device platform engineered to deliver consistent, controlled aerosolized medication to the upper-posterior nasal cavity using anatomical nozzle routing and a silicone-plate atomizing tip; designed for dual nostril dosing without propellants.
Self-administered single-use intranasal combination therapy for acute headache
A single-use, prescription combination product intended to translate clinic-based sphenopalatine ganglion (SPG) blockade into a patient self-administered intranasal therapy for rapid relief of acute migraine and cluster headache.
OFX-001
A self-administered, intranasal treatment designed to interrupt an acute pain attack in as little as 15 minutes by delivering medication to the upper-posterior nasal cavity.
Services
Partnering with pharmaceutical companies, investors, and research organizations to co-develop intranasal therapeutics and device–drug combination products, supported by accelerator and grant relationships.
Partnering with pharmaceutical companies, investors, and research organizations to co-develop intranasal therapeutics and device–drug combination products, supported by accelerator and grant relationships.
Expertise Areas
- Targeted intranasal drug delivery
- Device development and commercialization
- Preclinical development of device–drug combination products
- Formulation development for intranasal therapeutics
Key Technologies
- Targeted intranasal drug delivery
- Nose-to-brain neural targeting (olfactory and trigeminal pathways)
- Propellant-free aerosolized atomization
- Multi-stage mechanical dose actuation
News & Updates
Support for pre-clinical development of nasal headache disorder treatment.
Funding to develop Relaspen, a rapid migraine treatment.
Participation in a program to support SBIR proposal development.
Recognition by NC Biotech as a top life science startup.
Support for pre-clinical development of nasal headache disorder treatment.
Funding to develop Relaspen, a rapid migraine treatment.
Participation in a program to support SBIR proposal development.
Recognition by NC Biotech as a top life science startup.